Zimmer Biomet reports Q3 adjusted EPS $1.74, consensus $1.73

Reports Q3 revenue $1.82B, consensus $1.8B. “We are pleased with the strong performance we delivered in the third quarter, despite our ERP implementation challenges,” said Ivan Tornos, Zimmer Biomet’s (ZBH) president and CEO. “I am proud of the team and how they came together to manage the ERP issues and mitigate the negative impact on the Company’s performance for the year, positioning us to focus on our exciting innovation pipeline and planned new product introductions. We look forward to delivering on our strategic priorities and advancing our mission to help millions of people alleviate pain and improve their quality of life.”